BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus

IUBMB Life

Volumn 64, Issue 7, 2012, Pages 595-602

  Fairfax, Kirsten ^a   MacKay, Ian R ^a   MacKay, Fabienne ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Atacicept; B cells; B1 B cells; BAFF; Belimumab; Benlysta; BLyS; IL 10; Lymphostat B; T cells

Indexed keywords

ANTIMALARIAL AGENT; ATACICEPT; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; BELIMUMAB; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; PLACEBO; TABALUMAB; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

B LYMPHOCYTE; CELL HYPERPLASIA; CELL SURVIVAL; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HYPERGAMMAGLOBULINEMIA; LYMPHADENOPATHY; MACROPHAGE; MONOCYTE; NEUTROPHIL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, MONOCLONAL; B-CELL ACTIVATING FACTOR; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; DRUG DESIGN; EUROPEAN UNION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; RECOMBINANT FUSION PROTEINS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84862536209     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1046     Document Type: Review

References (63)

1. Moore, P. A., Belvedere, O., Orr, A., Pieri, K., LaFleur, D. W., et al. (1999) BlyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285, 260-263.
2. Schneider, P., Mackay, F., Steiner, V., Hofmann, K., Bodmer, J. L., et al. (1999) BAFF, a novel ligand of the tumor necrosis factor (TNF) family, stimulates B-cell growth. J. Exp. Med. 189, 1747-1756.
3. 2-terminal kinase. J. Biol. Chem. 274, 15978-15981.
4. Shu, H.-B., Hu, W.-H., and, Johnson, H., (1999) TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J. Leuk. Biol. 65, 680-683.
5. Mackay, F., Woodcock, S. A., Lawton, P., Ambrose, C., Baetscher, M., (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190, 1697-1710.
6. Thompson, J. S., Schneider, P., Kalled, S. L., Wang, L., Lefevre, E. A., et al. (2000) BAFF binds to the TNF receptor-like molecule BCMA and is important for maintaining the peripheral B cell population. J. Exp. Med. 192, 129-135.
7. Liu, Y., Hong, X., Kappler, J., Jiang, L., Zhang, R., et al. (2003) Ligand-receptor binding revealed by the TNF family member TALL-1. Nature 423, 49-56.
8. Batten, M., Groom, J., Cachero, T. G., Qian, F., Schneider, P., et al. (2000) BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 192, 1453-1465.
9. Schiemann, B., Gommerman, J. L., Vora, K., Cachero, T. G., Shulga-Morskaya, S., et al. (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293, 2111-2114.
10. Gross, J. A., Dillon, S. R., Mudri, S., Johnston, J., Littau, A., et al. (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 15, 289-302.
11. Day, E. S., Cachero, T. G., Qian, F., Sun, Y., Wen, D., et al. (2005) Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 44, 1919-1931.
12. Mackay, F., Figgett, W. A., Saulep, D., Lepage, M., and, Hibbs, M. L., (2010) B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol. Rev. 237, 205-225.
13. Baker, K. P., Edwards, B. M., Main, S. H., Choi, G. H., Wager, R. E., et al. (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B Lymphocyte Stimulator. Arthritis Rheum 48, 3253-3265.
14. Thompson, J. S., Bixler, S. A., Qian, F., Vora, K., Scott, M. L., et al. (2001) BAFF-R, a novel TNF receptor that specifically interacts with BAFF. Science 293, 2108-2111.
15. Shulga-Morskaya, S., Dobles, M., Walsh, M. E., Ng, L. G., MacKay, F., et al. (2004) B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J. Immunol. 173, 2331-2341.
16. Xu, S., and, Lam, K.-P., (2001) B-cell maturation protein, which binds the Tumor Necrosis Factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol. Cell. Biol. 21, 4067-4074.
17. O'Connor, B. P., Raman, V. S., Erickson, L. D., Cook, W. J., Weaver, L. K., et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91-97.
18. Benson, M. J., Dillon, S. R., Castigli, E., Geha, R. S., Xu, S., et al. (2008) Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol. 180, 3655-3659.
19. Yan, M., Wang, H., Chan, B., Roose-Girma, M., Erickson, S., et al. (2001) Activation and accumulation of B cells in TACI-deficient mice. Nature Immunol. 2, 638-643.
20. Seshasayee, D., Valdez, P., Yan, M., Dixit, V. M., Tumas, D., et al. (2003) Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18, 279-288.
21. von Bulow, G.-U., van Deursen, J. M., and, Bram, R. J., (2001) Regulation of the T-independent humoral response by TACI. Immunity 14, 573-582.
22. Ozcan, E., Garibyan, L., Lee, J. J., Bram, R. J., Lam, K. P., et al. (2009) Transmembrane activator, calcium modulator, and cyclophilin ligand interactor drives plasma cell differentiation in LPS-activated B cells. J. Allergy Clin. Immunol. 123, 1277-1286 e1275.
23. Bossen, C., Cachero, T. G., Tardivel, A., Ingold, K., Willen, L., et al. (2008) TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 111, 1004-1012.
24. Schneider, P., Takatsuka, H., Wilson, A., Mackay, F., Tardivel, A., et al. (2001) Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J. Exp. Med. 194, 1691-1697.
25. Kayagaki, N., Yan, M., Seshasayee, D., Wang, H., Lee, W., et al. (2002) BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity 10, 515-524.
26. Release, H.G.S.P. Human Genome Sciences and Glaxosmithkline announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus, November 2nd, 2009. Available at:. Accessed on April 26, 2012.
27. Fletcher, C. A., Sutherland, A. P., Groom, J. R., Batten, M. L., Ng, L. G., et al. (2006). Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur. J. Immunol. 36, 2504-2014.
28. Stohl, W., Metyas, S., Tan, S. M., Cheema, G. S., Oamar, B., et al. (2003) B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 48, 3475-3486.
29. Zhang, J., Roschke, V., Baker, K. P., Wang, Z., Alarcon, G. S., et al. (2001) A role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166, 6-10.
30. Navarra, S. V., Guzman, R. M., Gallacher, A. E., Hall, S., Levy, R. A., et al. (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721-731.
31. Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., et al. (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 61, 1143-1151.
32. Vollenhoven, R., Zamani, O., Wallace, D,., Tagzova, D., M. J., et al. (2010) Belimumab, a BLys-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study. Ann. Rheum. Dis. 69 (Suppl 3) p. 1 Section 74.
33. Navarra, S., Ilianova, E., Bae, S., Guzman, R., Tanasescu, C., et al. (2010) Belimumab, a BLys-specific inhibitor, reduced disease activity, flares, and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Ann. Rheum. Dis. 69 (Suppl 3) p. 1 Section 555. Available at:, 1. Accessed on April 26, 2012.
34. Zonana-Nacach, A., Barr, S. G., Magder, L. S., and, Petri, M., (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43, 1801-1808.
35. Chatham, W. W., and, Kimberly, R. P., (2001) Treatment of lupus with corticosteroids. Lupus 10, 140-147.
36. Darce, J. R., Arendt, B. K., Wu, X., and, Jelinek, D. F., (2007) Regulated expression of BAFF-binding receptors during human B cell differentiation. J. Immunol. 179, 7276-7286.
37. Stohl, W., Hiepe, F., Latinis, K. M., Thomas, M., Scheinberg, M. A., et al. (2012) Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum, 2012 Jan 24. Epub ahead of print.
38. Wallace, D. J., Stohl, W., Furie, R. A., Lisse, J. R., McKay, J. D., et al. (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168-1178.
39. Bernasconi, N. L., Traggiai, E., and, Lanzavecchia, A., (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199-2202.
40. Release, H.G.S.P. Human Genome Sciences announces presentation of additional Phase 3 SLE study results for Benlysta(R) (Belimumab) at international congress on SLE, June 25th, 2010. Available at:. Accessed on April 26, 2012.
41. Levy, R. A., Ilianova, E., Ionescu, R., Yu, C. L., Kang, Y. M., et al. (2010) Belimumab, a BLys-specific inhibitor, significantly reduced autoantibodies and normalized low complement in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Ann. Rheum. Dis. 69 (Suppl 3), 1. Available at:, 1.
42. Release, H.G.S.P. Human Genome Sciences and GlaxoSmithKline announce presentation at EULAR of BLISS-52 Phase 3 SLE study results for Benlysta (Belimumab), June 17th, 2010. Available at:. Accessed on April 26, 2012.
43. Waldmann, T. A., Iio, A., Ogawa, M., McIntyre, O. R., and, Strober, W., (1976) The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma. J. Immunol. 117, 1139-1144.
44. Thien, M., Phan, T. G., Gardam, S., Amesbury, M., Basten, A., et al. (2004) Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20, 785-798.
45. Chatham, W., Stohl, W., Merrill, J. T., Gruhn, W., Aranow, C., et al. (2007) Changes in circulating B-cell subtype counts, autoantibody levels and immunoglobulins that associate with therapeutic responsiveness in SLE to BLys protein antagonism by belimumab. Ann. Rheum. Dis. 66 (Suppl 11), 459. Available at:.
46. Ding, H., Wang, L., Wu, X., Yan, J., He, Y., et al. (2010) Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice. J. Cell. Mol. Med. 14, 1717-1725.
47. Hsieh, C., (2011) "Belimumab for systemic lupus erythematosus". American College of Rheumatology Hotline. Available at:. Accessed on May 16, 2012.
48. Hayes, E., (2009) Market snapshot: after Benlysta breakthrough, how high the sky in lupus? BioPharmaToday. Available at:. Accessed on April 26, 2012.
49. Gross, J. A., Johnston, J., Mudri, S., Enselman, R., Dillon, S. R., et al. (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404, 995-950.
50. Tak, P. P., Thurlings, R. M., Rossier, C., Nestorov, I., Dimic, A., et al. (2008) Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 58, 61-72.
51. NCT00573157, U. N.I.o.H. The efficacy and safety of atacicept in combination with mycophenolate mofetil used to treat lupus nephritis, March 2009. Available at:. Accessed on April 26, 2012.
52. Genovese, M. C., M. E., Biagini, M., Bojin, S., and, J. Sloan-Lancaster,. (2009) Phase 2 study of safety and efficacy of a novel Anti-BAFF monoclonal antibody, in patients with RA treated with methotrexate (MTX). American College of Rheumatology National Meeting, 2009, Philadelphia.
53. Yanaba, K., Bouaziz, J. D., Haas, K. M., Poe, J. C., Fujimoto, M., et al. (2008) A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28, 639-650.
54. Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D., and, S. M. Anderton,. (2002) B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3, 944-950.
55. Gray, D, and, Gray, M., (2010) What are regulatory B cells? Eur. J. Immunol. 40, 2677-2679.
56. Chun, H. Y., Chung, J. W., Kim, H. A., Yun, J. M., Jeon, J. Y., et al. (2007) Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 27, 461-466.
57. Huard, B., Schneider, P., Mauri, D., Tschopp, J., and, French, L. E., (2001) T cell costimulation by the TNF ligand BAFF. J. Immunol. 167, 6225-6231.
58. Ng, L. G., Sutherland, A. P., Newton, R., Qian, F., Cachero, T. G., et al. (2004) B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol. 173, 807-817.
59. Tsantikos, E., Oracki, S. A., Quilici, C., Anderson, G. P., Tarlinton, D. M., et al. (2010) Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6. J. Immunol. 184, 1348-1360.
60. Groom, J. R., Fletcher, C. A., Walters, S. N., Grey, S. T., Watt, S. V., et al. (2007) BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med. 204, 1959-1971.
61. Kamen, D. L., (2009) How can we reduce the risk of serious infection for patients with systemic lupus erythematosus? Arthritis Res. Ther. 11, 129.
62. Smith, K. D., (2006) Lupus nephritis: toll the trigger! J. Am. Soc. Nephrol. 17, 3273-3275.
63. Verdolini, R., Bugatti, L., Giangiacomi, M., Nicolini, M., Filosa, G., et al. (2002) Systemic lupus erythematosus induced by Epstein-Barr virus infection. Br. J. Dermatol. 146, 877-881.